A practical reference on lyophilized peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-10. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Bacteria are enclosed in a cell envelope, that protects the interior from the exterior. It generally consists of a plasma membrane covered by a cell wall which, for some bacteria, is covered by a third layer, a gelatinous bacterial capsule. The capsule may be polysaccharide as in pneumococci, meningococci or polypeptide as Bacillus anthracis or hyaluronic acid as in streptococci. Mycoplasma only possess the cell membrane. The cell envelope gives rigidity to the cell and separates the interior of the cell from its environment, serving as a protective mechanical and chemical filter. The cell wall consists of peptidoglycan and acts as an additional barrier against exterior forces. The cell wall acts to protect the cell mechanically and chemically from its environment, and is an additional layer of protection to the cell membrane. It also prevents the cell from expanding and bursting (cytolysis) from osmotic pressure due to a hypotonic environment. The DNA of a bacterium typically consists of a single circular chromosome that is in direct contact with the cytoplasm in a region called the nucleoid. Some bacteria contain multiple circular or even linear chromosomes. The cytoplasm also contains ribosomes and various inclusions where transcription takes place alongside translation. Extrachromosomal DNA as plasmids, are usually circular and encode additional genes, such as those of antibiotic resistance. Linear bacterial plasmids have been identified in several species of spirochete bacteria, including species of Borrelia which causes Lyme disease.
Annealing: This is a thermal treatment generally used to soften the material being drawn; to modify the microstructure, the mechanical properties, and the machining characteristics of the steel; and to remove internal stresses in the product. Depending on the material and desired final characteristics, annealing may be used before, during (between passes), or after the cold drawing operation.
A sperm donor will usually be required to enter into a contract with a sperm bank to supply his semen, typically for a period of six to 24 months depending on the number of pregnancies which the sperm bank intends to produce from the donor. The contract may also specify the place and hours for donation, a requirement to notify the sperm bank in the case the donor acquires a sexual infection, and a requirement not to have intercourse or to masturbate for a period of usually 2–3 days before making a donation. A sperm donor generally produces and collects sperm at a sperm bank or clinic by masturbation in a private room or cabin, known as a 'men's production room' (UK), 'donor cabin' (DK), or a masturbatorium (US). Many of these facilities contain pornography such as videos/DVD, magazines, and/or photographs which may assist the donor in becoming aroused in order to facilitate production of the ejaculate, also known as the "semen sample" but the increasing usage of porn in the U.S. has dulled many men to its effects. Often, using any lubricant, saliva, oil, or anything else to lubricate and stimulate the genitals is prohibited, as it can contaminate the semen sample and have negative impacts on the quality and health of sperm. In some circumstances, it may also be possible for semen from donors to be collected during sexual intercourse with the use of a collection condom which results in higher sperm counts.
Sources: en.wikipedia.org
Additionally, the intent of the regulations is to create a system that "should be a unified, standardized, and orderly processing of waste oil collection and improvement of the transportation system". The second set of regulations by the city of Beijing, called the "Beijing Municipal Solid Waste Regulations", was passed in September 2011. The regulations specifically target the two sources of gutter oil: food waste and used oil. The central government intends for these two sets of regulations to serve as national examples, yet wants every municipality nationally to find their own solutions to the food waste and gutter oil problem. A nationwide campaign was set in motion in August 2011 to crack down on the widespread production and selling of gutter oil. The law enforcement campaign uncovered 100 gutter oil manufacturers and arrested more than 800 people allegedly involved in the production and sale of gutter oil. In April 2012, another crackdown occurred with an additional 100 arrests made and 13 illegal workshops closed down across four provinces. According to a notice released jointly by the Supreme People's Court, the Supreme People's Procuratorate and the Ministry of Public Security, the death penalty will now be an option when prosecuting more serious cases of gutter oil manufacturing in the country. More severe punishments will also be given out to government and public officials who fail to properly address matters related to gutter oil.
Ernst Brun Jr. (born December 4, 1990) is an American football tight end. He previously played for the Washington Redskins. He previously played in college at Iowa State as well as the 2015 United States National American Football Team in the 2015 IFAF World Championship.
December 12, 2005: Law concerning the treatment of repeat offenses. March 23, 2006: Law concerning equal pay between women and men. March 31, 2006: Law for equal opportunities. April 4, 2006: Law strengthening the prevention and repression of violence within couples or committed against minors. July 24, 2006: Law concerning immigration and integration. January 31, 2007: Law aiming to promote equal access for women and men to electoral mandates and elective functions (mandatory parity for municipalities with more than 3,500 inhabitants and in regional executives; alternates for general councilors, both of different genders; reduced public aid for a political party in case of non-compliance with parity for legislative election candidacies). This law will be followed by the laws of February 26 and July 23, 2008, concerning the facilitation of equal access between women and men to certain mandates and elected functions, as well as to social and professional responsibilities. March 5, 2007: Law concerning the prevention of delinquency. March 14, 2007: Creation of "3919," a national telephone number for victims and witnesses of domestic violence. April 13, 2007: Decree concerning the methods of calculation and sharing of family allowances in the case of alternating residence of children at each parent's home and amending the Social Security Code (second part: Decrees in the Council of State). August 1, 2007: Law authorizing the ratification of the Council of Europe Convention on Action against Trafficking in Human Beings.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.